RecruitingNCT05353868

Gut Microbiota in the Progression of Alpha-synucleinopathies

Gut Microbiota in the Progression of Alpha-synucleinopathies: a Prospective Follow-up Study

Sponsor

Chinese University of Hong Kong

Enrollment

490 participants

Start Date

Feb 1, 2022

Study Type

OBSERVATIONAL

Conditions

REM Sleep Behavior Disorder

Summary

The aim of this study is to correlate baseline gut microbiota features and the progression of neurodegeneration in the established cohort of patients with early Parkinson's disease.

Eligibility

Inclusion Criteria1

recruit from the subjects who completed the baseline study

Exclusion Criteria3

The use of probiotics or antibiotics within three months prior to sample collection;
Pre-existing gastrointestinal diseases, such as inflammatory bowel disease.
Not capable of giving informed consent for participation of the study.

Interventions

OTHERNo intervention

No intervention

Locations(1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05353868

Related Trials

IMPACT 360 for Parkinson's Disease

NCT074432931 location

Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder

NCT064674611 location